tbuckley/cabot-search huggingface dataset:
Evaluation of Focal Adhesion Kinase Gene Expression in Leukemia and Cancer Cell Lines Using Combined Molecular Cytogenetic Investigations and Quantitative Real Time RT-PCR.
Authors: Lydia Campos, Andrei Tchirkov, Jerome Cornillon, Mirella Mihaescu, Michel Giollant, Simone Piselli, Philippe Vago, Michele Cottier
Journal: Blood (2004)
Targeted Next-Generation Sequencing (NGS) Enables for the First Time the Detection of Point Mutations, Molecular Insertions and Deletions, as Well as Leukemia-Specific Fusion Genes in AML in a Single Procedure.
Authors: Alexander Kohlmann, Vera Grossmann, Hans-Ulrich Klein, Sonja Schindela, Martin Dugas, Susanne Schnittger, Wolfgang Kern, Torsten Haferlach, Claudia Haferlach
Journal: Blood (2009)
Hematopoietic Stem Cells and Primitive Progenitors Express Leukemia-Associated Antigens That May Be Targets for Graft-Versus-Leukemia Effect or for Vaccine-Based Immunotherapy in Chronic Myeloid Leukemia.
Authors: Agnes S.M. Yong, Keyvan Keyvanfar, Rhoda Eniafe, Bipin N. Savani, Elaine M. Sloand, John M. Goldman, A. John Barrett
Journal: Blood (2006)
Sixty seconds on . . . snus
Authors: Nigel Hawkes
Journal: BMJ (2017)

Don’t confuse categories. Hygge is Danish and means a cosy lifestyle. Billy is an IKEA bookcase (from Sweden) that’s colonised the world. Both are better advertisements for Nordic life than those grim crime novels that fetishise serial killers in the snow.

A form of tobacco, sold in pouches and stuck under the upper lip, a peculiarity of Sweden and Norway. Ingvar Kamprad, IKEA’s founder, …
Arsenic Containing Triple-Agent Therapy for Acute Promyelocytic Leukemia-Comparison of Tetra-Arsenic Tetra-Sulfide vs. Arsenic Trioxide in the Long-Term Follow-up at a Single Hospital.
Authors: Shu-Lan Wu, Dao-Pei Lu, Yan-Li Zhao, Lan-Qing Liang, Jun-Bao He, Wei Zou, Xin-Hong Fei, Bin Jiang, Fu-Xiang Shan, Ping-Di Yang, Jie Zhao, Chun-Rong Tong
Journal: Blood (2010)
Advanced Glycation End Products, Oxidation Products, and the Extent of Atherosclerosis During the VA Diabetes Trial and Follow-up Study
Authors: Aramesh Saremi, Scott Howell, Dawn C. Schwenke, Gideon Bahn, Paul J. Beisswenger, Peter D. Reaven
Journal: Diabetes Care (2017)

To determine whether plasma levels of advanced glycation end products and oxidation products play a role in the development of atherosclerosis in patients with type 2 diabetes (T2D) over nearly 10 years of the VA Diabetes Trial and Follow-up Study.Baseline plasma levels of methylglyoxal hydroimidazolone, Nε-carboxymethyl lysine, Nε-carboxyethyl lysine (CEL), 3-deoxyglucosone hydroimidazolone and glyoxal hydroimidazolone (G-H1), 2-aminoadipic acid (2-AAA), and methionine sulfoxide were measured in a total of 411 participants, who underwent ultrasound assessment of carotid intima-media thickness (CIMT), and computed tomography scanning of coronary artery calcification (CAC) and abdominal aortic artery calcification (AAC) after an average of 10 years of follow-up.In risk factor-adjusted multivariable regression models, G-H1 was associated with the extent of CIMT and CAC. In addition, 2-AAA was strongly associated with the extent of CAC, and CEL was strongly associated with the extent of AAC. The combination of specific advanced glycation end products and oxidation products (G-H1 and 2-AAA) was strongly associated with all measures of subclinical atherosclerosis.Specific advanced glycation end products and metabolic oxidation products are associated with the severity of subclinical atherosclerosis over the long term and may play an important role in the "negative metabolic memory" of macrovascular complications in people with long-standing T2D.
Immunophenotypic, Cytogenetic and Functional Characterization of Circulating Endothelial Cells in Myelodysplastic Syndromes.
Authors: Matteo G. Della Porta, Luca Malcovati, Gian Matteo Rigolin, Vittorio Rosti, Erica Travaglino, Emanuela Boveri, Anna Galli, Sabrina Boggi, Rosangela Invernizzi, Mario Cazzola
Journal: Blood (2006)
Long Term Follow-Up Shows No Clinical Benefit for CD34+ Selection of Autologous Transplants Following Myeloablative Therapy in Patients with Newly Diagnosed Myeloma : An EBMT Phase III Randomized Study.
Authors: Jean-Henri Bourhis, Yasmina Bouko, Serge Koscielny, Hildegard Greinix, Gunter Derigs, Gilles Salles, Walter Feremans, Marleen Bakkus, Jane Apperley, Diana Samson, Bo Bjorkstrand, Dietger Niederwieser, Gosta Gahrton, Jose-Luis Pico, Hartmut Goldschmidt
Journal: Blood (2004)
Identifying patients with node-positive prostate cancer who may benefit from adjuvant pelvic radiation following prostatectomy.
Authors: Monica Erin Shukla, Chandana A. Reddy, Kevin L. Stephans, Andrew J. Stephenson, Eric A. Klein, Jorge A. Garcia, Robert Dreicer, Rahul D. Tendulkar
Journal: Journal of Clinical Oncology (2012)

195 Background: Three PRTs address the role adjuvant radiotherapy (RT) following radical prostatectomy (RP) in men with locally advanced and/or margin positive prostate cancer (PCa), one of which demonstrated an improvement in overall survival by the addition of early RT. Not addressed in these studies is the role of adjuvant RT in lymph node positive (LN+) PCa. Methods: We reviewed an IRB-approved prospective database at the Cleveland Clinic and identified 84 men with non-metastatic, LN+ PCa treated with RP from 1987-2010. Men receiving neoadjuvant therapy or adjuvant RT were excluded from this analysis. Pelvic failure (PF) was defined as recurrence in the prostate bed or pelvic LN up to the common iliacs. Distant failures (DF) were defined as any LN recurrence beyond the common iliacs, bone, or other solid organ metastases. Kaplan-Meier estimates of pelvic failure (PF), distant failure (DF) and overall survival (OS) were conducted. Results: Median follow-up was 6 years. The median initial PSA was 10.1 ng/mL, 50% had Gleason 7, 12% had Gleason 8, 31% had Gleason 9 disease. The median number of LNs dissected was 11 (range 1-49) and 36% had &gt;1 LN+. Extracapsular extension was present in 90%, seminal vesicle invasion in 66%, and surgical margins positive in 55%. The 6 week post-operative PSA was undetectable (&lt;0.2 ng/ml) in 58%. Overall, 41% received immediate androgen deprivation therapy (ADT), and 45% received delayed ADT after biochemical or clinical failure, while 23% received salvage RT and 22% received chemotherapy. The 10-year OS was 61%. Clinically documented PF and DF occurred in 14% and 24%, respectively. Gleason score was the factor most predictive of PF, DF, and OS. Comparing Gleason score of ≤7 vs. ≥8, the 5-year PF rate was 3% vs. 24% (p=0.006), the 5-year DF rate was 2% vs. 37% (p&lt;0.0001), and 5-year OS was 97% vs. 74% (p&lt;0.0001), respectively. The number of LN+ was not prognostic. Conclusions: Men with Gleason score ≥8 LN+ PCa have a high rate of pelvic recurrence, and pelvic radiation may be worthy of prospective investigation.
Study of Cytotoxic Effects of K562/Adm Cells by Low Frequency Ultrasound Enchance Adriamycin.
Authors: Bao-An Chen, Qing-Qi Meng, Chong Gao, Jia-Hua Ding, Yun-Yu Sun, Jun Wang, Jian Cheng, Gang Zhao, Fei Fei, Ning-Na Chen
Journal: Blood (2005)
Hodgkin Lymphoma in Very Young Children Can Be Treated Successfully without Radiation Therapy.
Authors: Asim F. Belgaumi, Amani A. Al-Kofide, Nicey Joseph, Yasser Khafaga, Rubina J. Malik, Walid Mourad, Gamal-Eldin H. Mohamed, Rajih S. Sabbah
Journal: Blood (2006)
Targeting MUC1-C inhibits the AKT-S6K1-elF4A pathway regulating TIGAR translation in colorectal cancer
Authors: Rehan Ahmad, Maroof Alam, Masanori Hasegawa, Yasumitsu Uchida, Omar Al-Obaid, Surender Kharbanda, Donald Kufe
Journal: Molecular Cancer (2017)

Colorectal cancer is third most common malignancy and is the second most common cause of cancer-related death. The MUC1 heterodimeric protein is aberrantly overexpressed in colorectal cancer and has been linked to poor outcomes in this disease. Here, we investigate the effects of the MUC1-C subunit inhibitor (GO-203), which disrupts MUC1-C homo-oligomerization, on human colorectal cancer cells.TIGAR mRNA level was determined using qRT-PCR. Western blotting was used to measure TIGAR protein level and AKT-mTOR-S6K1 pathways. Reactive oxygen species and apoptosis were measured by flow cytometry. Effect of MUC1-C peptide, GO-203 was studied on colorectal xenograft tumors. Immunohistochemistry was utilized for TIGAR staining.Treatment of MUC1-overexpressing SKCO-1 and Colo-205 colon cancer cells with GO-203 was associated with downregulation of the TP53-inducible glycolysis and apoptosis regulator (TIGAR) protein. TIGAR promotes the shunting of glycolytic intermediates into the pentose phosphate pathway and thus is of importance for maintaining redox balance. We show that GO-203-induced suppression of TIGAR is mediated by inhibition of AKT and the downstream mTOR pathway. The results also demonstrate that targeting MUC1-C blocks eIF4A cap-dependent translation of TIGAR. In concert with these results, GO-203-induced suppression of TIGAR was associated with decreases in GSH levels. GO-203 treatment also resulted in increases in reactive oxygen species (ROS) and loss of mitochondrial transmembrane potential. Consistent with these results, GO-203 inhibited the growth of colon cancer cells in vitro and as xenografts in nude mice. Inhibition of MUC1-C also downregulated TIGAR expression in xenograft tissues.These findings indicate that MUC1-C is a potential target for the treatment of colorectal cancer. Colorectal cancer patients who overexpress MUC1-C may be candidates for treatment with the MUC1-C inhibitor alone or in combination therapy with other agents.
Bendamustine in Combination with Thalidomide and Prednisolone (BPT) in Patients with Refractory or Relapsed Multiple Myeloma (MM): Preliminary Results of a Phase I Clinical Trial.
Authors: Wolfram Poenisch, Marta Rozanski, Sabine Leiblein, Hartmut Goldschmidt, Almut Wegner, Dietger Niederwieser
Journal: Blood (2004)
Klotho, an anti-aging gene, acts as a tumor suppressor and inhibitor of IGF-1R signaling in diffuse large B cell lymphoma
Authors: Xiangxiang Zhou, Xiaosheng Fang, Yujie Jiang, Lingyun Geng, Xinyu Li, Ying Li, Kang Lu, Peipei Li, Xiao Lv, Xin Wang
Journal: Journal of Hematology & Oncology (2017)

Klotho, is a transmembrane protein, performs as a circulating hormone and upstream modulator of the insulin-like growth factor-1 receptor (IGF-1R), fibroblast growth factor (FGF), and Wnt signaling pathways. These pathways are involved in the development and progression of B cell lymphoma. We aimed to explore the expression pattern and functional mechanism of Klotho in diffuse large B cell lymphoma (DLBCL). Immunohistochemistry (IHC) and western blotting were performed to detect the expression level of Klotho in DLBCL patients and cell lines. Tumor suppressive effect of Klotho was determined by both in vitro and in vivo studies. Signaling pathway activity was assessed by western blotting. Remarkable lower expression levels of Klotho were observed in DLBCL patients and cell lines. Enforced expression of Klotho could significantly induce cell apoptosis and inhibit tumor growth in DLBCL. Upregulation of Klotho resulted in declined activation of IGF-1R signaling, accompanied with decreased phosphorylation of its downstream targets, including AKT and ERK1/2. Moreover, xenograft model treated with either Klotho overexpression vector or recombinant human Klotho administration presented restrained tumor growth and lower Ki67 staining. Our findings establish that Klotho performs as a tumor suppressor and modulator of IGF-1R signaling in DLBCL. Targeting Klotho may provide novel strategies for future therapeutic intervention.
Amplified selectivity in cognitive processing implements the neural gain model of norepinephrine function
Authors: Eran Eldar, Jonathan D. Cohen, Yael Niv
Journal: Behavioral and Brain Sciences (2016)

Abstract Previous work has suggested that an interaction between local selective (e.g., glutamatergic) excitation and global gain modulation (via norepinephrine) amplifies selectivity in information processing. Mather et al. extend this existing theory by suggesting that localized gain modulation may further mediate this effect – an interesting prospect that invites new theoretical and experimental work.
Nano-on-micro fibrous extracellular matrices for scalable expansion of human ES/iPS cells
Authors: Li Liu, Ken-ichiro Kamei, Momoko Yoshioka, Minako Nakajima, Junjun Li, Nanae Fujimoto, Shiho Terada, Yumie Tokunaga, Yoshie Koyama, Hideki Sato, Kouichi Hasegawa, Norio Nakatsuji, Yong Chen
Journal: Biomaterials (2017)
Relationship of opioid analgesic (OA) use at 3 months and overall survival in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
Authors: Susan Halabi, William Kevin Kelly, Ellen B Kaplan, Eric Jay Small
Journal: Journal of Clinical Oncology (2012)

200 Background: Baseline pain has been shown to be a significant predictor of overall survival (OS) in mCRPC pts. The objectives of this analysis were to identify predictors of OA use at 3-months after initiating frontline chemotherapy, and to determine if OA use at 3-months predicts overall OS in mCRPC pts. Methods: Data from CALGB 90401, a phase III trial of 1,050 mCRPC pts randomized with equal probability to receive docetaxel, prednisone with either bevacizumab or placebo was analyzed. OA use was collected at baseline and at 3-month follow-up. OA use was classified as: pts not on OA at baseline and at 3-months (OA1); OA at baseline but not on at 3-months (OA2); No OA at baseline but on OA at 3-months (OA3); and OA at both time points (OA4). The logistic regression method was utilized to identify predictors of OA use at 3-months. Furthermore, the proportional hazards model was used to assess the prognostic significance of OA use in predicting OS adjusting for stratification factors. Results: 836 pts had complete OA data. The overall distribution of pts with the associated median survival times is presented in the table. There was a linear trend between OA use and overall survival (log-rank p-value&lt;0.0001). The multivariable hazard ratio (HR) for death was 1.34 (95% CI=1.12-1.61) comparing OA4 vs. OA1. In multivariable logistic regression model, statistically significant predictors of OA at 3-months were OA use at baseline, hemoglobin, and alkaline phosphatase. Conclusions: The strongest predictor of OA use at 3-months was use at baseline. In addition, this analysis shows that OA use after initiating chemotherapy is a statistically significant predictor of overall survival in mCRPC pts. These results require prospective validation. [Table: see text]
Steady State Sickle Cell Anemia Is Associated with Increased Formation of Erythrocyte-Derived Microparticles and Acceleration of Thrombin Generation.
Authors: Mourad Chaari, Katia Stankovic, Vasso Galea, Francoise Robert, Amir Khaterchi, François Lionnet, Micheline Maier, Robert Girot, Grigorios T. Gerotziafas, Ismail Elalamy
Journal: Blood (2009)
Prognostic value of the 3q27 and 18q21 translocations for diffuse large B-cell lymphoma and follicular lymphoma in the rituximab era.
Authors: R. Watanabe, N. Tomita, C. Matsumoto, Y. Hattori, S. Matsuura, H. Takasaki, C. Hashimoto, H. Fujita, S. Fujisawa, Y. Ishigatsubo
Journal: Journal of Clinical Oncology (2011)

e18513 Background: The 3q27 and 18q21 translocations are major chromosomal alterations in B cell lymphoma. Bcl-6 on chromosome 3q27 encodes B-cell lymphoma (Bcl)-6 protein, which inhibits differentiation to plasma cells. The 18q21 translocation cause the constitutive activation and increased expression of the antiapoptotic Bcl-2 protein. However, the prognostic impact of these translocations in the rituximab (R) era is unclear. We aim to determine the frequency of the 3q27 and 18q21 translocations in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) and to evaluate their prognostic impact in the R era. Methods: The study included 93 patients with DLBCL and 98 with FL; they had abnormal karyotypes that had been detected using G-banding at diagnosis. The patients underwent R-CHOP therapy: doxorubicin, cyclophosphamide, vincristine, prednisolone, and R; median follow-up period was 29 months. Results: The 3q27 and 18q21 translocations were detected in 14 (15%) and 22 (24%), respectively, of the patients with DLBCL patients and in 14 (14%) and 77 (79%), respectively, of those with FL. The 2-year overall survival (OS) rates for patient with DLBCL and for those with FL were 79.0% and 95.1%, respectively; the 2-year progression-free survival (PFS) rates were 70.1% and 62.0%, respectively. The 2-year OS and PFS rates did not significantly differ between the 3q27, 18q21, and other chromosomal abnormality groups for DLBCL (2-year OS, 65.3% vs. 85.7% vs. 79.3%, respectively; 2-year PFS 59.2% vs. 65.4% vs. 73.6%, respectively; not significant) and FL (2-year OS, 85.7% vs. 94.7 vs. 100%, respectively; 2-year PFS, 42.9% vs. 64.0% vs. 60.6%; NS). These rates did not significantly differ between the patients with 3q27 translocation-positive DLBCL and those with 3q27 translocation-positive FL or between the patients with 18q27 translocation-positive DLBCL and those with 18q27 translocation-positive FL. Conclusions: In the R era, the presence of the 3q27 and 18q21 translocations is not correlated with the clinical outcome of patients with DLBCL or FL.
IGHV-Mutation Status, IGHV-Gene Usage and Chromosomal Aberrations In CLL: Pooled Analysis within First-Line Clinical Trials of the German CLL Study Group (GCLLSG)
Authors: Andreas Bühler, Thorsten Zenz, Dirk Winkler, Raymonde Busch, Kirsten Fischer, Anna Fink, Clemens Wendtner, Barbara Eichhorst, Jennifer Edelmann, Michael Hallek, Hartmut Doehner, Stephan Stilgenbauer
Journal: Blood (2010)
NIMG-64DIFFERENTIATION OF EARLY PROGRESSION AND PSEUOPROGRESSION IN GLIOBLASTOMA BY MAGNETIC RESONANCE SPECTROSCOPY
Authors: Tsutsui Taishi, Miyashita Katsuyoshi, Furuta Takuya, Kinoshita Masashi, Ueda Fumiaki, Nakada Mitsutoshi
Journal: Neuro-Oncology (2015)

OBJECTIVES: Early enlargement of enhanced lesions is relatively common after concurrent radiation and chemotherapy with temozolomide in glioblastoma (GBM) patients. Differentiation of early progression (EP) and pseudoprogression (PsP) is clinically important in choice of treatment. Methionine-PET is reported to be helpful in differentiating EP from PsP. This study investigates clinical usefulness of magnetic resonance spectroscopy (MRS) in distinguishing EP from PsP. MATERIALS AND METHODS: A retrospective analysis was performed in patients with GBM who underwent tumor removal at our institution between 1998 and 2015. Forty-two out of 173 GBM patients (24%) showed enlargement of enhanced lesions within 6 months after chemoradiotherapy. Thirteen patients (17 lesions) with MRS were included in this study. PsP was diagnosed by histological findings or by retrospectively when these enhanced lesions regressed or remained stable without salvage therapy. We focused the peak of choline (Cho: 3.2 ppm), creatine (Cr: 3.0 ppm) and lactate/lipid (LL: 1.3 ppm), and calculated the ratio of LL/Cho, Cho/Cr and LL/Cr on MRS. We analyzed the receiver operating characteristic (ROC) curve to acquire each sensitivity, specificity and cutoff value and examined usefulness of these ratios by area under the ROC curve (AUC). RESULTS: Eight lesions diagnosed as EP and 9 lesions as PsP. The sensitivity, specificity and AUC on LL/Cho was 89%, 75% and 0.833 (p = 0.015); Cho/Cr (44%, 88%, 0,625), LL/Cr (78%, 88%, 0.847 (p = 0.015)). CONCLUSIONS: Our data suggest that EP from PsP could be differentiated by the ratio of LL/Cho and LL/Cr on MRS.
FTY720, a New and Alternative Strategy for Treating Blast Crisis CML and Ph1 ALL Patients.
Authors: Ramasamy Santhanam, Paolo Neviani, Anna Eiring, Joshua Oaks, Mario Notari, Bradley W. Blaser, Shujun Liu, Rossana Trotta, Natarajan Muthusamy, Guido Marcucci, Carlo Gambacorti, Denis-Claude Roy, Michael A. Caligiuri, Clara D. Bloomfield, Ching-Shih Chen, John C. Byrd, Danilo Perrotti
Journal: Blood (2006)
Rituximab Overcomes Sex as a Strong Adverse Prognostic Factor for Treatment Outcome in Patients with Follicular Lymphoma: Analysis of Patients Treated with Rituximab/CHOP or CHOP in Randomized Trials of the German Low Grade Lymphoma Study Group (GLSG).
Authors: Christian Buske, Eva Hoster, Martin H. Dreyling, Roswitha Forstpointner, Michael Kneba, Norbert Schmitz, Rudolf Schmits, Bernd Metzner, Michael Hallek, Eva Lengfelder, Wolfgang Hiddemann, Michael Unterhalt
Journal: Blood (2009)
Enhancement of Hematopoietic Stem Cell Engraftment and Graft vs. Leukemia Effect Induced by Matched and Haploidentically Mismatched Allograft Using Multi-Donor Stem Cell Transplantation (MDT).
Authors: Michael Y. Shapira, Reuven Or, Igor B. Resnick, Simcha Samuel, Benjamin Gesundheit, Shimon Slavin
Journal: Blood (2006)
A patient with suspected miscarriage is found to have hypertension, renal failure, and thrombocytopenia: case presentation
Authors: Chris M Laing, Rhys Roberts, Liz Lightstone, Alison Graham, Terry H Cook, Shaun Summers, Charles D Pusey
Journal: BMJ (2007)

A 46 year old white woman presented to her local casualty department.She had been experiencing vaginal bleeding for 10 days, and the bleeding had become particularly heavy in the past three days.She had also felt generally unwell for around a week with malaise, fatigue, headaches, anorexia, and vomiting.She and her partner had been trying to conceive.Her last menstrual period had been 10 weeks ago and she had recently tested positive with a urinary (β human chorionic gonadotrophin) pregnancy testing kit.She had three children from a previous partner.Two of these pregnancies were complicated by hypertension from 36 weeks onwards.She thought that she may have had two miscarriages the previous year, which had not been investigated.The previous year she had a measured blood pressure of 165/90 mm Hg.She gave a history suggestive of Raynaud's syndrome but had no other symptoms or past medical history of note.She was taking no regular medication.
Pediatric Reverse Triage—Uncomfortable but Real Decision Making for Community Preparedness
Authors: Frederick M. Burkle
Journal: JAMA Pediatrics (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal